Tevogen Reports Major Clinical Milestone: Expands HLA Coverage of its Investigational Precision T Cell Therapy for Acute and Long COVID

Core Insights - Tevogen Bio Holdings Inc. has achieved a clinical milestone by completing T cell target identification for five additional human leukocyte antigen (HLA) restrictions, expanding the accessibility of its ExacTcell™ platform [1][4] - The identification of these additional HLA targets allows for the treatment of approximately 65% of the U.S. population, significantly increasing coverage for minority populations [2][3] - The investigational T cell therapy, TVGN 489, has demonstrated 100% viral clearance in high-risk patients with COVID-19, with no reinfections or cases of Long COVID reported [7] Company Developments - The ExacTcell™ platform employs advanced immunological screening to identify immune system targets across various HLA types, aiming to provide treatments for a broader range of infectious diseases and cancers [4] - The selection of additional HLA targets is aimed at ensuring equitable access to treatments for patients of diverse racial and ethnic backgrounds [3] Market Context - Long COVID has affected approximately 35 million U.S. adults, leading to an estimated economic burden of $2.6 trillion to $3.7 trillion, highlighting the urgent need for effective treatments like Tevogen's T cell therapies [3] - The expansion of patient eligibility through multi-HLA targeting is a significant step towards universal T cell therapeutics, enhancing the potential market for Tevogen's products [7]